Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases 2018

Theranexus announces appointment of Jérôme Martinez to its Board of Directors
13/12/2018
Download PDF File (370 Ko)

Theranexus September 30th cash position and business update
09/11/2018
Download PDF File (369 Ko)

Theranexus announces inclusion of last patient in phase II trial of drug candidate THN102 on narcolepsy patients

29/10/2018
Download PDF File (371 Ko)

Theranexus plans to extend its phase 2 pipeline with a third program

15/10/2018
Download PDF File (382 Ko)

Theranexus announces that Rodolphe Besserve will join its Board of Directors

11/10/2018
Download PDF File (368 Ko)

Theranexus announces a new European patent protecting THN201, its drug candidate for the treatment of neurocognitive disorders including those associated with Alzheimers

09/10/2018
Download PDF File (373 Ko)

 Recognition of the scientific excellence of Theranexus

01/10/2018
Download PDF File (379 Ko)

Theranexus announces its first half 2018 results

27/09/2018
Download PDF File (335 Ko)

Theranexus obtains the authorization to start a Phase 1b clinical trial with its drug candidate THN201 in neurocognitive disorders due to Alzheimer's disease

26/09/2018
Download PDF file (384 Ko)

Theranexus announces the inclusion of the first patient in its phase 2 clinical trial evaluating its drug candidate THN102 in excessive daytime sleepiness (EDS) in patients with Parkinson's disease

16/07/2018
Download the PDF file (397 Ko)

Theranexus presents new data on the stimulating effect of its drug candidate THN 102

05/07/2018
Download PDF file (306 Ko)

Half-year information on the liquidity contract (in French)

02/07/2018
Download PDF file (197 Ko)

Theranexus announces German Authorities approval for its phase 2 clinical trial in Parkinson's disease

26/06/2018
Download the PDF (375 Ko)

Theranexus announces the publication of a scientific article on the mechanism of action of drug candidate THN102 in the international journal of neuropsychopharmacology
22/05/2018
Download PDF file (262 Ko)

Theranexus publishes its cash position as at 31st March 2018
15/05/2018
Download PDF file (204 Ko)

Theranexus presentation at the International Connexins Symposium (Vancouver 14-15 May 2018)
07/05/2018
Download PDF file (273 Ko)

Publication of 2017 reference document (in French)
27/04/2018
Download PDF file (153 Ko)

Oral presentation of Theranexus at the 9th European congress on narcolepsy 5 and 6 may in Montpellier
02/05/2018
Download PDF File (279 Ko)

Theranexus announces its 2017 annual results and presents an update on the progress of its clinical trials
26/04/2018
Download PDF File (427 Ko)

THN102 obtains Investigational New Drug status from the Food & Drug Administration (FDA)
23/04/2018
Download PDF file (755 Ko)

Theranexus announces a successful clinical pharmacokinetic study as part of the development of its drug candidates THN201 and THN101
21/03/2018
Download PDF File (309 Ko)

Theranexus and the Collège de France sign a research agreement on Astrocyte-Neuron interactions
15/03/2018
Download PDF File (187 Ko)

Theranexus announces issuance of European patent covering its drug candidate thn102 for treatment of narcolepsy and Parkinson's disease>
11/01/2018
Télécharger le PDF (801 Ko)

Theranexus announces the first European approval for its phase 2 clinical trial with THN 102 in Parkinson's disease patients
19/04/2018
Download PDF file (278 Ko)

Information on the total number of voting rights and shares (french only)
05/01/2018
Download PDF File (656 Ko)